Idogen AB (publ) has received the go-ahead from both the Swedish and Norwegian Medical Products Agencies to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in hemophilia A. The study's primary purpose is to show that the treatment is safe and to obtain preliminary data on the potential treatment effect.
1st Jan change | Capi. | |
---|---|---|
+8.66% | 105B | |
-0.85% | 104B | |
+5.79% | 22.94B | |
-12.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.26% | 16.96B | |
+8.08% | 14.16B | |
+39.55% | 12.63B |